EP4264617A1 - Procédé de fabrication de formes médicamenteuses optimisées pour un patient - Google Patents
Procédé de fabrication de formes médicamenteuses optimisées pour un patientInfo
- Publication number
- EP4264617A1 EP4264617A1 EP21820273.7A EP21820273A EP4264617A1 EP 4264617 A1 EP4264617 A1 EP 4264617A1 EP 21820273 A EP21820273 A EP 21820273A EP 4264617 A1 EP4264617 A1 EP 4264617A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- dosage form
- patient
- active
- active substance
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002552 dosage form Substances 0.000 title claims abstract description 160
- 238000004519 manufacturing process Methods 0.000 title claims description 11
- 238000000034 method Methods 0.000 claims abstract description 156
- 238000007639 printing Methods 0.000 claims abstract description 73
- 239000003814 drug Substances 0.000 claims abstract description 33
- 238000004458 analytical method Methods 0.000 claims abstract description 22
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 239000013543 active substance Substances 0.000 claims description 135
- 239000004480 active ingredient Substances 0.000 claims description 120
- 201000010099 disease Diseases 0.000 claims description 77
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 77
- 229940079593 drug Drugs 0.000 claims description 31
- 230000000694 effects Effects 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 210000004185 liver Anatomy 0.000 claims description 6
- 208000010125 myocardial infarction Diseases 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 5
- 238000009826 distribution Methods 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 239000003146 anticoagulant agent Substances 0.000 claims description 4
- 229940127219 anticoagulant drug Drugs 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 4
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 3
- 239000002220 antihypertensive agent Substances 0.000 claims description 3
- 230000036772 blood pressure Effects 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 239000003862 glucocorticoid Substances 0.000 claims description 3
- 208000014951 hematologic disease Diseases 0.000 claims description 3
- 239000002348 inosinate dehydrogenase inhibitor Substances 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 239000005541 ACE inhibitor Substances 0.000 claims description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
- 229940123583 Factor Xa inhibitor Drugs 0.000 claims description 2
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 claims description 2
- 206010061217 Infestation Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 229940122388 Thrombin inhibitor Drugs 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 2
- 230000000721 bacterilogical effect Effects 0.000 claims description 2
- 239000002876 beta blocker Substances 0.000 claims description 2
- 229940097320 beta blocking agent Drugs 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 claims description 2
- 238000004820 blood count Methods 0.000 claims description 2
- 230000036765 blood level Effects 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- 229940030606 diuretics Drugs 0.000 claims description 2
- 239000003210 dopamine receptor blocking agent Substances 0.000 claims description 2
- 230000035622 drinking Effects 0.000 claims description 2
- 235000006694 eating habits Nutrition 0.000 claims description 2
- 239000003792 electrolyte Substances 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 230000008986 metabolic interaction Effects 0.000 claims description 2
- 230000004060 metabolic process Effects 0.000 claims description 2
- 230000003071 parasitic effect Effects 0.000 claims description 2
- 230000037081 physical activity Effects 0.000 claims description 2
- 239000003868 thrombin inhibitor Substances 0.000 claims description 2
- 208000003663 ventricular fibrillation Diseases 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 210000001835 viscera Anatomy 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 229940082632 vitamin b12 and folic acid Drugs 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 229940019333 vitamin k antagonists Drugs 0.000 claims description 2
- 229940127088 antihypertensive drug Drugs 0.000 claims 2
- 229940046731 calcineurin inhibitors Drugs 0.000 claims 2
- 230000000771 oncological effect Effects 0.000 claims 2
- 229940037128 systemic glucocorticoids Drugs 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 1
- 229940082629 iron antianemic preparations Drugs 0.000 claims 1
- 208000037911 visceral disease Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 description 78
- 230000008569 process Effects 0.000 description 57
- 239000000203 mixture Substances 0.000 description 22
- 239000003018 immunosuppressive agent Substances 0.000 description 19
- 238000001125 extrusion Methods 0.000 description 17
- 229960003444 immunosuppressant agent Drugs 0.000 description 16
- 238000010146 3D printing Methods 0.000 description 15
- 239000007787 solid Substances 0.000 description 14
- 239000003826 tablet Substances 0.000 description 13
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 239000007788 liquid Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000008186 active pharmaceutical agent Substances 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 239000011230 binding agent Substances 0.000 description 7
- 230000009969 flowable effect Effects 0.000 description 7
- 239000000969 carrier Substances 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 238000009474 hot melt extrusion Methods 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- 239000004014 plasticizer Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 238000002844 melting Methods 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 239000000976 ink Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000007711 solidification Methods 0.000 description 4
- 230000008023 solidification Effects 0.000 description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 239000010408 film Substances 0.000 description 3
- 229940125721 immunosuppressive agent Drugs 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical class OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 229960001967 tacrolimus Drugs 0.000 description 3
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010013654 Drug abuse Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000007899 abuse-deterrent tablet Substances 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 238000013473 artificial intelligence Methods 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- -1 dabigatran Chemical compound 0.000 description 2
- 238000013135 deep learning Methods 0.000 description 2
- 229920006237 degradable polymer Polymers 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229960004866 mycophenolate mofetil Drugs 0.000 description 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 2
- 229960000951 mycophenolic acid Drugs 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 239000003505 polymerization initiator Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 229940122739 Calcineurin inhibitor Drugs 0.000 description 1
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 description 1
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 101001090860 Homo sapiens Myeloblastin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229940121740 Inosine monophosphate dehydrogenase inhibitor Drugs 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 102100034681 Myeloblastin Human genes 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229960003886 apixaban Drugs 0.000 description 1
- GLGAUBPACOBAMV-DOFZRALJSA-N arachidonylcyclopropylamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NC1CC1 GLGAUBPACOBAMV-DOFZRALJSA-N 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 239000004566 building material Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 229960003850 dabigatran Drugs 0.000 description 1
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007641 inkjet printing Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 239000007912 modified release tablet Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940046781 other immunosuppressants in atc Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229960004923 phenprocoumon Drugs 0.000 description 1
- DQDAYGNAKTZFIW-UHFFFAOYSA-N phenprocoumon Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC)C1=CC=CC=C1 DQDAYGNAKTZFIW-UHFFFAOYSA-N 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
- 229960001879 ropinirole Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 239000000003 vaginal tablet Substances 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y70/00—Materials specially adapted for additive manufacturing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y80/00—Products made by additive manufacturing
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y10/00—Processes of additive manufacturing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y50/00—Data acquisition or data processing for additive manufacturing
- B33Y50/02—Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes
Abstract
La présente invention concerne des procédés dans le domaine des produits pharmaceutiques personnalisés. Plus précisément, l'invention concerne des procédés de fabrication de formes médicamenteuses pharmaceutiques qui sont produites par impression 3D et/ou 2D, une large gamme de paramètres relatifs à l'administration de la forme médicamenteuse pouvant être modifiés en fonction de l'analyse des données spécifiques du patient et de la maladie et adaptés pendant le traitement du patient. De cette manière, la qualité du traitement peut être améliorée pour les patients à l'avenir et être considérablement améliorée en ce qui concerne la sécurité du patient.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20212320 | 2020-12-07 | ||
| PCT/EP2021/084678 WO2022135919A1 (fr) | 2020-12-07 | 2021-12-07 | Procédé de fabrication de formes médicamenteuses optimisées pour un patient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4264617A1 true EP4264617A1 (fr) | 2023-10-25 |
Family
ID=73747869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP21820273.7A Pending EP4264617A1 (fr) | 2020-12-07 | 2021-12-07 | Procédé de fabrication de formes médicamenteuses optimisées pour un patient |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP4264617A1 (fr) |
| JP (1) | JP2024518009A (fr) |
| CN (1) | CN117203709A (fr) |
| WO (1) | WO2022135919A1 (fr) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6070107A (en) | 1997-04-02 | 2000-05-30 | Stratasys, Inc. | Water soluble rapid prototyping support and mold material |
| WO2016038356A1 (fr) | 2014-09-08 | 2016-03-17 | University Of Central Lancashire | Production d'une forme pharmaceutique solide |
| US20180290386A1 (en) * | 2015-11-05 | 2018-10-11 | Vitae Industries, Inc. | Method and apparatus for safe and accurate 3d printing |
| US20170185745A1 (en) * | 2015-12-26 | 2017-06-29 | Dan Wartski | Technologies for customized drug provisioning |
| US10259164B2 (en) | 2016-06-22 | 2019-04-16 | Massachusetts Institute Of Technology | Methods and apparatus for 3D printing of point cloud data |
| CN112806078B (zh) | 2018-08-03 | 2024-03-19 | 上海诺基亚贝尔股份有限公司 | 网络节点之间的资源调度 |
| WO2020240030A1 (fr) | 2019-05-31 | 2020-12-03 | Dihesys Digital Health Systems Gmbh | Formes pharmaceutiques polyvalentes et procédé pour leur fabrication |
| US20220226250A1 (en) | 2019-05-31 | 2022-07-21 | Dihesys Digital Health Systems Gmbh | Additive Method For 3D Printing Active Ingredient-Containing Objects |
-
2021
- 2021-12-07 WO PCT/EP2021/084678 patent/WO2022135919A1/fr active Application Filing
- 2021-12-07 JP JP2023534728A patent/JP2024518009A/ja active Pending
- 2021-12-07 CN CN202180092164.XA patent/CN117203709A/zh active Pending
- 2021-12-07 EP EP21820273.7A patent/EP4264617A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024518009A (ja) | 2024-04-24 |
| WO2022135919A1 (fr) | 2022-06-30 |
| CN117203709A (zh) | 2023-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vaz et al. | 3D printing as a promising tool in personalized medicine | |
| DE69826290T2 (de) | Pharmazeutische zusammensetzungen zur kontrollierten freigabe von wirkstoffen | |
| DE3030622C2 (de) | Teilbare Tablette mit Retardeffekt für die Abgabe von Metoprolol oder Oxprenolol | |
| DE69920689T2 (de) | Vorrichtungen zum Aufrechterhalten eines gewünschten therapeutischen Medikamenteneffekts über einen verlängerten Therapiezeitraum | |
| DE69429826T3 (de) | Opioid-formulierungen zur schmerzbehandlung | |
| DE69919713T2 (de) | Pharmazeutische zubereitung mit verzögerter wirkstofffreisetzung von phenytoin natrium | |
| Joo et al. | The advent of a novel manufacturing technology in pharmaceutics: Superiority of fused deposition modeling 3D printer | |
| Serrano et al. | 3D printing technologies in personalized medicine, nanomedicines, and biopharmaceuticals | |
| EP0868171B1 (fr) | Implants a liberation de medicaments par phases | |
| DE60126089T2 (de) | Verabreichungssystem | |
| DE19954421A1 (de) | Filmförmige Zubereitung zur biphasigen Freisetzung pharmakologisch wirksamer oder anderer Substanzen | |
| WO2001034121A2 (fr) | Preparation multicouche, se presentant sous forme de film, constituee de polymeres hydrophiles et permettant une liberation rapide d'agents actifs | |
| DE2950463A1 (de) | Gallensaeuren enthaltende pharmazeutische zubereitung mit verlaengerter wirkungsdauer | |
| Varghese et al. | 3D printing in the pharmaceutical sector: Advances and evidences | |
| EP3368017B1 (fr) | Comprimé optimisé a une haute dose contenant de la mesalazine | |
| DE69817848T2 (de) | Monolithsysteme enthaltend mindestens einer wirkstoff, bestehend aus drei schichten mit unterschiedlichen freisetzungmechanismus | |
| WO2020240030A1 (fr) | Formes pharmaceutiques polyvalentes et procédé pour leur fabrication | |
| Seoane-Viaño et al. | 3D printing of pharmaceutical products | |
| WO2020240028A1 (fr) | Procédé additif d'impression tridimensionnelle d'objets contenant des principes actifs | |
| EP4264617A1 (fr) | Procédé de fabrication de formes médicamenteuses optimisées pour un patient | |
| EP3975987A1 (fr) | Formes galéniques pharmaceutiques et procédé pour les produire | |
| WO2021115887A1 (fr) | Procédé et dispositif d'impression par points pour la fabrication additive de formes galéniques contenant des principes actifs | |
| WO2021198308A1 (fr) | Appareil et procédé d'impression tridimensionnelle de mélanges de médicaments pour former des formes d'administration pharmaceutique à l'aide d'un dispositif d'alimentation en matière rotatif ou mobile | |
| Qi et al. | Personalized Polypills Produced by Fused Deposition Modeling 3D Printing | |
| EP1923056B1 (fr) | Forme galénique individuelle |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20230720 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) |